Hemastatx SRL
Hemastatx reported total assets of 200,755 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jul 2026).
The score of Hemastatx shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Hemastatx's annual accounts
| 2025 | |
|---|---|
| Net result | −280,078 € |
| Equity | −280,077 € |
| Cash | 180,810 € |
| EBITDA | −113,093 € |
| Total assets | 200,755 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jul 2026
Hemastatx's financial analysis
- Solvency-139.5%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Hemastatx
Hemastatx's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1019.406.058
- VAT number
- BE1019406058
- Peppol
- Registered · 0208:1019406058 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Jan 2025
- Registered office
- 6041 Charleroi
- Latest accounts
- 2025 · filed on 30 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Hemastatx (SRL) has been based in Charleroi since 2025, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 280,078 € and equity of −280,077 €; its revenue is not published. Its solvency stands at -139.5%, below the median of its sector (58.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Hemastatx
Companies in the same business, of comparable size and area, outside its group.
- 3D Fibroscreen Research and experimental development on natural sciences and engineering Charleroi · balance sheet 501,766 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- Elkedonia Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet 228,425 €
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- Flindr Labs Manufacture of pharmaceutical preparations Ghent · balance sheet 262,929 €
- Ergotrics Research and experimental development on natural sciences and engineering Turnhout · balance sheet 376,384 €
- Groovy.Bio Manufacture of pharmaceutical preparations Evergem · balance sheet 744,069 €
- BONT Research and experimental development on natural sciences and engineering Kasterlee · balance sheet 307,284 €
Frequently asked questions about Hemastatx
What is the revenue of Hemastatx?
Hemastatx files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Hemastatx?
In Belgium, the VAT number is the company number prefixed with BE: BE1019406058 for Hemastatx, if the company is VAT-registered. Its company number (CBE) is 1019.406.058.
Where is the registered office of Hemastatx?
According to the CBE register, the registered office of Hemastatx is in 6041 Charleroi.
What is the equity of Hemastatx?
At the close of the 2025 financial year, the equity of Hemastatx amounts to -280,077 €, a solvency of -139.5% of total assets.
Who manages Hemastatx?
The register lists 2 active mandates at Hemastatx. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Hemastatx
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →